Evidence map›Paper›PMID 37816710›Full record

ArticleCell death & disease2023

SIRT1 and HSP90α feed-forward circuit safeguards chromosome segregation integrity in diffuse large B cell lymphomas.

Emilia Białopiotrowicz-Data, Monika Noyszewska-Kania, Ewa Jabłońska, Tomasz Sewastianik, Dorota Komar, Sonia Dębek, Filip Garbicz, Magdalena Wojtas, Maciej Szydłowski, Anna Polak and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Emilia Białopiotrowicz-DataDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Monika Noyszewska-KaniaDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Ewa JabłońskaDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Tomasz SewastianikDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Dorota KomarDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Sonia DębekDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Filip GarbiczDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Magdalena WojtasDepartment of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Maciej SzydłowskiDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Anna PolakDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.ORCID 0000-0001-8686-3429
Patryk GórniakDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Przemysław JuszczyńskiDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. pjuszczynski@ihit.waw.pl.ORCID 0000-0001-7215-0444
Instytut Hematologii i Transfuzjologi · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults, exhibiting highly heterogenous clinical behavior and complex molecular background. In addition to the genetic complexity, different DLBCL subsets exhibit phenotypic features independent of the genetic background. For example, a subset of DLBCLs is distinguished by increased oxidative phosphorylation and unique transcriptional features, including overexpression of certain mitochondrial genes and a molecular chaperone, heat shock protein HSP90α (termed "OxPhos" DLBCLs). In this study, we identified a feed-forward pathogenetic circuit linking HSP90α and SIRT1 in OxPhos DLBCLs. The expression of the inducible HSP90α isoform remains under SIRT1-mediated regulation. SIRT1 knockdown or chemical inhibition reduced HSP90α expression in a mechanism involving HSF1 transcription factor, whereas HSP90 inhibition reduced SIRT1 protein stability, indicating that HSP90 chaperones SIRT1. SIRT1-HSP90α interaction in DLBCL cells was confirmed by co-immunoprecipitation and proximity ligation assay (PLA). The number of SIRT1-HSP90α complexes in PLA was significantly higher in OxPhos- dependent than -independent cells. Importantly, SIRT1-HSP90α interactions in OxPhos DLBCLs markedly increased in mitosis, suggesting a specific role of the complex during this cell cycle phase. RNAi-mediated and chemical inhibition of SIRT1 and/or HSP90 significantly increased the number of cells with chromosome segregation errors (multipolar spindle formation, anaphase bridges and lagging chromosomes). Finally, chemical SIRT1 inhibitors induced dose-dependent cytotoxicity in OxPhos-dependent DLBCL cell lines and synergized with the HSP90 inhibitor. Taken together, our findings define a new OxPhos-DLBCL-specific pathogenetic loop involving SIRT1 and HSP90α that regulates chromosome dynamics during mitosis and may be exploited therapeutically.

Indexed as

Chromosome SegregationHSP90 Heat-Shock ProteinsLymphoma, Large B-Cell, DiffuseSirtuin 1HumansMolecular ChaperonesHSP90AA1 protein, humanHSP90 Heat-Shock ProteinsMolecular ChaperonesSIRT1 protein, humanSirtuin 1

Identifiers

PMID37816710
PMCPMC10564908
OpenAlexW4387515697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.